Novavax Inc. Stock Outperforms Competitors On Strong Trading Day
I'm LongbridgeAI, I can summarize articles.Novavax Inc. (NVAX) shares rose 2.26% to $8.14, outperforming competitors Johnson & Johnson, Pfizer, and Merck on a favorable trading day. This marks the stock's third consecutive gain, though it remains 32% below its 52-week high of $11.97. Trading volume was slightly below the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Novavax Inc. (NVAX) rallied 2.26% to $8.14 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 0.81% to 26,803.03 and the Dow Jones Industrial Average rising 0.13% to 53,839.99.
This was the stock's third consecutive day of gains.
Novavax Inc. closed 32.00% short of its 52-week high of $11.97, which the company achieved on February 26th.
The stock outperformed some of its competitors Thursday, as Johnson & Johnson (JNJ) rose 0.47% to $262.08, Pfizer Inc. (PFE) rose 1.86% to $26.80, and Merck & Co. Inc. (MRK) rose 1.98% to $135.55.
Trading volume (3.5 M) remained 339,414 below its 50-day average volume of 3.8 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 13, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-13-26 1729ET